Columbia Trust Co 01012016 Has $1.80 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Columbia Trust Co 01012016 raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,153 shares of the medical research company’s stock after acquiring an additional 456 shares during the period. Thermo Fisher Scientific comprises approximately 1.0% of Columbia Trust Co 01012016’s holdings, making the stock its 25th largest holding. Columbia Trust Co 01012016’s holdings in Thermo Fisher Scientific were worth $1,802,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. State Street Corp raised its holdings in Thermo Fisher Scientific by 2.1% in the 2nd quarter. State Street Corp now owns 15,553,658 shares of the medical research company’s stock valued at $7,850,342,000 after acquiring an additional 318,930 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Thermo Fisher Scientific by 19.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,316,751 shares of the medical research company’s stock worth $6,717,901,000 after buying an additional 2,133,690 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 6,070,059 shares of the medical research company’s stock worth $3,052,801,000 after buying an additional 173,240 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Thermo Fisher Scientific by 10.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,993,588 shares of the medical research company’s stock worth $2,014,647,000 after buying an additional 381,863 shares in the last quarter. Finally, Clearbridge Investments LLC raised its holdings in shares of Thermo Fisher Scientific by 0.8% in the 2nd quarter. Clearbridge Investments LLC now owns 2,956,545 shares of the medical research company’s stock worth $1,491,488,000 after buying an additional 24,684 shares in the last quarter. 85.47% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently issued reports on the company. Citigroup increased their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Thursday, October 28th. Argus increased their price target on Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 4th. Benchmark increased their price target on Thermo Fisher Scientific from $580.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, September 22nd. The Goldman Sachs Group upgraded Thermo Fisher Scientific from a “buy” rating to a “conviction-buy” rating in a research report on Thursday, September 23rd. Finally, SVB Leerink increased their price target on Thermo Fisher Scientific from $675.00 to $685.00 and gave the stock an “outperform” rating in a research report on Thursday, October 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $613.89.

TMO stock opened at $633.00 on Thursday. The business’s fifty day moving average is $606.29 and its 200-day moving average is $544.24. The company has a quick ratio of 2.56, a current ratio of 3.19 and a debt-to-equity ratio of 0.56. The company has a market cap of $249.43 billion, a P/E ratio of 29.41, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. Thermo Fisher Scientific Inc. has a twelve month low of $433.52 and a twelve month high of $651.57.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 27th. The medical research company reported $5.76 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.67 by $1.09. The company had revenue of $9.33 billion for the quarter, compared to the consensus estimate of $8.41 billion. Thermo Fisher Scientific had a return on equity of 28.14% and a net margin of 21.93%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.63 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.4 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 14th. Stockholders of record on Wednesday, December 15th will be paid a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.16%. The ex-dividend date of this dividend is Tuesday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 4.83%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Thursday, September 23rd that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 1.3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

In other Thermo Fisher Scientific news, COO Mark Stevenson sold 26,925 shares of Thermo Fisher Scientific stock in a transaction dated Monday, November 1st. The stock was sold at an average price of $632.69, for a total value of $17,035,178.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Stephen Williamson sold 22,550 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, November 2nd. The shares were sold at an average price of $638.10, for a total value of $14,389,155.00. The disclosure for this sale can be found here. Corporate insiders own 0.44% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Featured Story: What is the Russell 2000 Index?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.